54.50
전일 마감가:
$55.45
열려 있는:
$54.37
하루 거래량:
2.46M
Relative Volume:
1.03
시가총액:
$137.99B
수익:
$48.03B
순이익/손실:
$6.06B
주가수익비율:
21.81
EPS:
2.4983
순현금흐름:
$9.91B
1주 성능:
-7.00%
1개월 성능:
-0.82%
6개월 성능:
-4.39%
1년 성능:
+9.55%
사노피 ADR Stock (SNY) Company Profile
SNY을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
SNY
Sanofi Adr
|
54.50 | 137.99B | 48.03B | 6.06B | 9.91B | 2.4983 |
![]()
LLY
Lilly Eli Co
|
826.76 | 742.57B | 45.04B | 10.59B | 414.30M | 11.71 |
![]()
ABBV
Abbvie Inc
|
201.30 | 356.10B | 56.33B | 4.28B | 17.83B | 2.40 |
![]()
JNJ
Johnson Johnson
|
161.72 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
![]()
NVO
Novo Nordisk Adr
|
71.73 | 334.39B | 42.09B | 14.65B | 10.11B | 3.2833 |
![]()
MRK
Merck Co Inc
|
88.11 | 235.20B | 64.17B | 17.12B | 18.10B | 6.73 |
사노피 ADR Stock (SNY) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-03-21 | 개시 | Goldman | Neutral |
2025-01-30 | 업그레이드 | Deutsche Bank | Sell → Hold |
2024-07-26 | 재확인 | Argus | Buy |
2024-01-23 | 개시 | Morgan Stanley | Equal-Weight |
2024-01-16 | 재개 | UBS | Buy |
2023-12-05 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2023-10-30 | 다운그레이드 | Stifel | Buy → Hold |
2023-09-06 | 업그레이드 | Berenberg | Hold → Buy |
2023-07-14 | 개시 | HSBC Securities | Buy |
2023-04-28 | 다운그레이드 | Deutsche Bank | Hold → Sell |
2023-03-27 | 업그레이드 | Barclays | Equal Weight → Overweight |
2022-12-13 | 재개 | Morgan Stanley | Overweight |
2022-08-12 | 업그레이드 | Deutsche Bank | Sell → Hold |
2022-08-09 | 다운그레이드 | UBS | Buy → Neutral |
2022-05-23 | 개시 | SVB Leerink | Outperform |
2021-09-27 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
2021-01-15 | 개시 | Deutsche Bank | Sell |
2020-09-29 | 개시 | Berenberg | Hold |
2020-03-17 | 업그레이드 | Barclays | Underweight → Equal Weight |
2020-03-11 | 업그레이드 | Goldman | Neutral → Buy |
2020-02-11 | 개시 | SVB Leerink | Mkt Perform |
2020-01-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
2019-09-23 | 업그레이드 | Guggenheim | Neutral → Buy |
2019-09-20 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2019-09-03 | 개시 | Bernstein | Outperform |
2019-08-14 | 업그레이드 | UBS | Neutral → Buy |
2018-12-11 | 업그레이드 | Jefferies | Hold → Buy |
2018-11-01 | 업그레이드 | Barclays | Underweight → Equal Weight |
2018-10-09 | 개시 | Guggenheim | Neutral |
2018-09-10 | 업그레이드 | BofA/Merrill | Neutral → Buy |
2018-08-10 | 업그레이드 | Citigroup | Neutral → Buy |
2018-03-23 | 업그레이드 | Liberum | Hold → Buy |
2018-01-23 | 다운그레이드 | Barclays | Equal Weight → Underweight |
2017-12-06 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
2017-12-01 | 다운그레이드 | Morgan Stanley | Overweight → Underweight |
2017-11-15 | 업그레이드 | Barclays | Underweight → Equal Weight |
2017-08-30 | 업그레이드 | HSBC Securities | Reduce → Hold |
모두보기
사노피 ADR 주식(SNY)의 최신 뉴스
[Latest] Global Fabry Disease Treatment Market Size/Share Worth USD 7.02 Billion by 2034 at a 9.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value) - GlobeNewswire Inc.
4 healthcare stocks attractive on valuation and ESG risk - Morningstar.com.au
SNY Quantitative Stock Analysis - Nasdaq
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Bioengineered Protein Drugs Market Size to Cross USD 672.7 Billion by 2034, Growing at a CAGR of 6.2% - GlobeNewswire Inc.
Know Labs Inc (KNW) Stock: A Closer Look at the Market Potential - The News Heater
European Equities Traded in the US as ADRs Fall in Tuesday Trading - TradingView
Piper Sandler Shows Market Leadership With Jump To 83 RS Rating - Inkl
Sanofi ADR Shows Market Leadership With Jump To 82 RS Rating - Investor's Business Daily
Gold Field ADR Sees Its Composite Rating Rise To 99 - Inkl
ZEEKR Intelligent ADR Shows Rising Price Performance With Jump To 80 RS Rating - Inkl
Validea Detailed Fundamental AnalysisSNY - Nasdaq
Harrow Earns Relative Strength Rating Upgrade - Inkl
Sanofi ADR Earns RS Rating Upgrade - Investor's Business Daily
Newmont Earns RS Rating Upgrade - Inkl
What was Skechers U S A, Inc (SKX)’s performance in the last session? - US Post News
Sanofi ADR (SNY) requires closer examination - US Post News
Sanofi ADR (SNY): A Technical Analysis - The News Heater
GNPX’s Market Whiplash: -38.94% YTD Decline, -42.28% Plunge in 30 Days - The InvestChronicle
Applied Materials Inc’s Banking’s 100-Day Moving Average at 182.60: Will the Stock Break Through? - The InvestChronicle
ESPR’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Regeneron Pharmaceuticals Beats On Libtayo's Back, Unveils Dividend - Investor's Business Daily
Waltham biotech plans to raise $150M in IPO this week - The Business Journals
Sanofi Reports Strong Q4 Sales Growth, Plans €5 Billion Buyback in 2025 - GuruFocus.com
Sanofi ADR earnings beat by $0.53, revenue fell short of estimates - Investing.com South Africa
Sanofi ADR (SNY) Recovers 15.33% From Low: Are We There Yet? - Stocks Register
Sanofi: Informations relatives au nombre de droits de vote et d'actions - GlobeNewswire Inc.
AECOM (NYSE: ACM) Is A Blank Check For Growth - Stocks Register
Shares Of Pennymac Mortgage Investment Trust (NYSE: PMT): Are They Overvalued Compared To Others? - Stocks Register
사노피 ADR (SNY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):